Trial reportStroke2020
Thrombolysis With Alteplase at 0.6 mg/kg for Stroke With Unknown Time of Onset: A Randomized Controlled Trial.
Trial report in Stroke, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 14 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 14 syntheses or guidelines pooled it.
- Intravenous Thrombolysis Beyond the Conventional Time Window for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
- Methods for Analyzing the Modified Rankin Scale in Stroke Thrombolysis Trials: A Systematic Review and Methodological Framework.Journal of the American Heart Association · 2026Pooled it
- Safety Outcomes Following Intravenous Thrombolysis in Acute Ischemic Stroke: A Systematic Review and Network Meta-analysis.CNS drugs · 2026Pooled it
- Chinese stroke association guidelines on reperfusion therapy for acute ischaemic stroke 2024.Stroke and vascular neurology · 2025Guideline
- Comparing Early National Institutes of Health Stroke Scale Versus 90-Day Modified Rankin Scale Outcomes in Acute Ischemic Stroke Trials: A Systematic Review and Analysis.Journal of the American Heart Association · 2025Pooled it
- Safety and efficacy of intravenous thrombolytic therapy in the extended window up to 24 hours: A systematic review and meta-analysis.Annals of clinical and translational neurology · 2024Pooled it
- Outcomes of wake-up stroke undergoing mechanical thrombectomy: A systematic review and meta-analysis.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2024Pooled it
- Thrombolysis for Wake-Up Stroke Versus Non-Wake-Up Unwitnessed Stroke: EOS Individual Patient Data Meta-Analysis.Stroke · 2024Pooled it
- The Value of Applying Machine Learning in Predicting the Time of Symptom Onset in Stroke Patients: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2023Pooled it
- Systematic Review of Existing Stroke Guidelines: Case for a Change.BioMed research international · 2022Pooled it
- Intravenous thrombolytic treatment and endovascular thrombectomy for ischaemic wake-up stroke.The Cochrane database of systematic reviews · 2021Pooled it
- Safety of intravenous thrombolysis in stroke of unknown time of onset: A systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2021Pooled it
- Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data.Lancet (London, England) · 2020Pooled it
- Efficacy and Safety of Intravenous Thrombolytics in Ischemic Stroke Beyond the 4.5-Hour Time Window: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Tenecteplase, alteplase, and endovascular thrombectomy in extended-window acute ischemic stroke with intracranial large-vessel occlusion: a Bayesian network meta-analysis.Journal of neurology · 2026Article
- DWI-FLAIR mismatch versus perfusion-based selection for extended window thrombolysis in acute ischemic stroke: a meta-analysis of randomized controlled trials.Journal of thrombosis and thrombolysis · 2026Review
- Role of Low-Field MRI in Acute Stroke.Stroke · 2026Review
- Beyond Conventional Imaging: From Time-Based to Data-Driven Decision-Making in Acute Ischemic Stroke.Journal of atherosclerosis and thrombosis · 2026Review
- Development of tenecteplase for stroke thrombolysis: Japan's endeavor.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Efficacy and Safety of Intravenous Thrombolysis in the Extended Time Window for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose- We assessed whether lower-dose alteplase at 0.6 mg/kg is efficacious and safe for acute fluid-attenuated inversion recovery-negative stroke with unknown time of onset. Methods- This was an investigator-initiated, multicenter, randomized, open-label, blinded-end point trial. Patients met the standard indication criteria for intravenous thrombolysis other than a time last-known-well >4.5 hours (eg, wake-up stroke). Patients were randomly assigned (1:1) to receive alteplase at 0.6 mg/kg or standard medical treatment if magnetic resonance imaging showed acute ischemic lesion on diffusion-weighted imaging and no marked corresponding hyperintensity on fluid-attenuated inversion recovery. The primary outcome was a favorable outcome (90-day modified Rankin Scale score of 0-1). Results- Following the early stop and positive results of the WAKE-UP trial (Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke), this trial was prematurely terminated with 131 of the anticipated 300 patients (55 women; mean age, 74.4±12.2 years). Favorable outcome was comparable between the alteplase group (32/68, 47.1%) and the control group (28/58, 48.3%; relative risk [RR], 0.97 [95% CI, 0.68-1.41];
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.